Eileen Nash
4 Papers
19 Citations
Eileen Nash is an academic researcher. The author has contributed to research in topics: Rucaparib & Cancer. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Evaluation of absorption, distribution, metabolism, and excretion of [ 14 C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors
Mingxiang Liao,Simon Paul Watkins,Eileen Nash,Jeff Isaacson,Jeff Etter,Jeri Beltman,Rong Fan,Li Shen,Abdul Mutlib,Vendel Kemeny,Zsuzsanna Papai,Pascal van Tilburg,Jim J. Xiao +12 more
TL;DR: The data suggest that rucaparib is eliminated through multiple pathways, including metabolism and renal and biliary excretion, as well as the presence of metabolites in plasma.
Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.
Jim J. Xiao,Dorota Nowak,Rodryg Ramlau,Monika Tomaszewska-Kiecana,Piotr J. Wysocki,Jeff Isaacson,Jeri Beltman,Eileen Nash,Robert Kaczanowski,Gerhard Arold,Simon Paul Watkins +10 more
TL;DR: There was limited effect on peak concentration of the substrates at steady state, rucaparib 600 mg b.i.d. moderately inhibited CYP1A2, weakly inhibited CYp2C9, CYP2C19, and CYP3A, and marginally increased digoxin exposure.
19
A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
Mingxiang Liao,Krzysztof G. Jeziorski,Monika Tomaszewska-Kiecana,István Láng,Marek Jasiówka,Viera Skarbova,Piotr Centkowski,Rodryg Ramlau,Maria Górnaś,John Y. Lee,Sarah Edwards,Jenn Habeck,Eileen Nash,Nikolay Grechko,Jim J. Xiao +14 more
TL;DR: In this article, the effect of rucaparib on the pharmacokinetics of rosuvastatin and oral contraceptives in patients with advanced solid tumors and their safety was evaluated.
Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment
Nikolay Grechko,Viera Skarbova,Monika Tomaszewska-Kiecana,Rodryg Ramlau,Piotr Centkowski,Yvette Drew,Rafal Dziadziuszko,Milada Zemanova,Jeri Beltman,Eileen Nash,Jenn Habeck,Mingxiang Liao,Jim J. Xiao +12 more
TL;DR: In this paper, the authors investigated whether hepatic impairment affects the pharmacokinetics, safety, and tolerability of rucaparib in patients with advanced solid tumors, and the results suggest no starting dose adjustment is necessary for patients with moderate liver impairment; however, close safety monitoring is warranted.